» Articles » PMID: 21893367

Hallucinogenic Drugs in Pre-Columbian Mesoamerican Cultures

Overview
Journal Neurologia
Specialty Neurology
Date 2011 Sep 7
PMID 21893367
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The American continent is very rich in psychoactive plants and fungi, and many pre-Columbian Mesoamerican cultures used them for magical, therapeutic and religious purposes.

Objectives: The archaeological, ethno-historical and ethnographic evidence of the use of hallucinogenic substances in Mesoamerica is reviewed.

Results: Hallucinogenic cactus, plants and mushrooms were used to induce altered states of consciousness in healing rituals and religious ceremonies. The Maya drank balché (a mixture of honey and extracts of Lonchocarpus) in group ceremonies to achieve intoxication. Ritual enemas and other psychoactive substances were also used to induce states of trance. Olmec, Zapotec, Maya and Aztec used peyote, hallucinogenic mushrooms (teonanacatl: Psilocybe spp) and the seeds of ololiuhqui (Turbina corymbosa), that contain mescaline, psilocybin and lysergic acid amide, respectively. The skin of the toad Bufo spp contains bufotoxins with hallucinogenic properties, and was used since the Olmec period. Jimson weed (Datura stramonium), wild tobacco (Nicotiana rustica), water lily (Nymphaea ampla) and Salvia divinorum were used for their psychoactive effects. Mushroom stones dating from 3000 BC have been found in ritual contexts in Mesoamerica. Archaeological evidence of peyote use dates back to over 5000 years. Several chroniclers, mainly Fray Bernardino de Sahagún, described their effects in the sixteenth century.

Conclusions: The use of psychoactive substances was common in pre-Columbian Mesoamerican societies. Today, local shamans and healers still use them in ritual ceremonies in Mesoamerica.

Citing Articles

Psychedelics: Safety and Efficacy.

Miller N Int J Environ Res Public Health. 2025; 22(2).

PMID: 40003360 PMC: 11855591. DOI: 10.3390/ijerph22020134.


Latin American adults who regularly use macrodoses of psychedelics: a cross-sectional study.

Veliz-Garcia O, Domic-Siede M Sci Rep. 2024; 14(1):23921.

PMID: 39397094 PMC: 11471782. DOI: 10.1038/s41598-024-74590-3.


Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.

Egger K, Aicher H, Cumming P, Scheidegger M Cell Mol Life Sci. 2024; 81(1):395.

PMID: 39254764 PMC: 11387584. DOI: 10.1007/s00018-024-05353-6.


Unlocking the healing power of psilocybin: an overview of the role of psilocybin therapy in major depressive disorder, obsessive-compulsive disorder and substance use disorder.

Szafoni S, Greblowski P, Grabowska K, Wieckiewicz G Front Psychiatry. 2024; 15:1406888.

PMID: 38919636 PMC: 11196758. DOI: 10.3389/fpsyt.2024.1406888.


Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases.

Haniff Z, Bocharova M, Mantingh T, Rucker J, Velayudhan L, Taylor D Pharmacol Ther. 2024; 258:108641.

PMID: 38583670 PMC: 11847495. DOI: 10.1016/j.pharmthera.2024.108641.